KCM
VRTX icon

Key Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Key Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98K Hold
6
– – ﹤0.01% 518
2026
Q1 		$2.68K Hold
6
– – ﹤0.01% 481
2025
Q4 		$2.72K Buy
+6
New +$2.59K ﹤0.01% 360

Other funds holding VRTX

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Key Capital Management's VRTX Position: Q2 2026 in Review

Key Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 6 shares worth $2.98K. The position accounts for ﹤0.01% of the portfolio, ranked #518.

Key Capital Management first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 947 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Key Capital Management held 6 shares of Vertex Pharmaceuticals worth $2.98K as of Q2 2026.
  • Key Capital Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Key Capital Management's portfolio in Q2 2026, its #518 holding.
  • Key Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 947 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Key Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.